Syrspend SF | 2018 Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend® SF PH4 Polonini HC, da Silva SL, Brandao MAF, Bauters T, De Moerloose B, Ferreira AO International Journal of Pharmaceutical Compounding, 22(6), 516-526 The objective of this study was to evaluate the stability of oral suspensions compounded with SyrSpend SF PH4 and 14 commonly used active pharmaceutical ingredients. The beyond-use date of the final products (API + vehicle) was at least 90 days for all suspensions in the conditions tested. Read more SEE PRODUCT
Syrspend SF | 2018 Comparison of rheological and sedimentation behavior of commercially available suspending vehicles for oral pharmaceutical preparations Visser CJ, ten Seldam IEJ, van der Linden IJ, Hinrichs WLJ, Veenendaal RFH, Dijkers ECF, Woerdenbag HJ International Journal of Pharmaceutical Compounding, 22(3), 247-251 In this study, the rheological behavior of ready-to-use vehicles for oral pharmaceutical preparations was compared, and the sedimentation of paracetamol dispersed in these vehicles was investigated. With SuspendIt and SyrSpend SF PH4 (Liquid), very stable paracetamol suspensions were obtained. SyrSpend SF PH4 (Liquid) displayed somewhat higher viscosity. Read more SEE PRODUCT
Syrspend SF | 2018 Stability of regularly prescribed oral liquids formulated with SyrSpend® SF Uriel M, Gomez-Rincon C, Marro D Pharmazie, 73(4), 196-201 This research evaluated the stability of 12 oral liquid formulations in SyrSpend® SF. A beyond-use date (BUD) of 30 days was assigned to tiagabine HCl 1.0 mg/ml at RT, (90 days refrigerated). 60 days was assigned to chloral hydrate 100.0 mg/ml and 90 days to the rest (RT or refrigerated). Read more SEE PRODUCT
Pentravan | 2018 The effects of vaginal Gestrinone with Histone Deacetylase Inhibitors on endometriosis-related pain and endometrial proliferation – A short study Maia H jr, Haddad C, Saback W jr Journal of Clinical Case Studies, 3(1) The objective was to investigate the effects of vaginal valproic acid or resveratrol with vitamin D3 in Pentravan®, on deep endometriosis-associated pain in patients treated with gestrinone. They potentiated the effects of gestrinone in the first month of treatment; however, this difference disappeared in the subsequent months. Read more SEE PRODUCT
Pentravan | 2018 Treatment of endometriosis and leiomyoma with the association of miodesin and gestrinone in Pentravan through the vaginal route Maia H, Saback W, Haddad C, Sitya PR Journal of Clinical Review and Case Reports, 3(7), 1-5 The effects of Myodesin™ on uterine volume and pain scores were investigated in a group of patients with leiomyoma and endometriosis. Miodesin treatment increased the efficacy of Gestrinone to reduce pelvic pain and uterine volume in patients with endometriosis and leiomyoma. Read more SEE PRODUCT
TrichoConcept | 2018 Resveratrol, Blueberry, Cranberry and Raspberry exhibit protection effect to photodamaged hair de Souza Gomes J, Silva Rita M, da Cunha Altomare JM, Raposo NRB, Brandao MAF, Polonini HC Journal of Dermatology Research and Therapy, 4(2), 061 In this study, conditioners using blueberry, raspberry, cranberry and resveratrol in TrichoCond® were developed. Two out of the seven presented significative sun protection. Three samples of treated hair presented suitable results in maintenance of the cystine content after sun exposure. Conditioners containing resveratrol showed better protection against solar radiation. Read more SEE PRODUCT
Syrspend SF | 2017 Stability of Acetazolamide, Baclofen, Dipyridamole, Mebevarine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate oral suspensions in SyrSpend® SF PH4 Ferreira AO, Polonini HC, Loures da Silva S, Buzinari Aglio NC, Abreu J, Brandao MAF International Journal of Pharmaceutical Compounding, 21(4), 339-346 The objective of this study was to evaluate the stability of 7 commonly used APIs ingredients compounded in SyrSpend SF PH4. The beyond-use date of the final products (active pharmaceutical ingredient + vehicle) was at least 90 days for all suspensions with regard to both temperatures. Read more SEE PRODUCT
StripMax | 2017 Technological device for manufacturing transdermal films: possible applications to the individualized treatment for erectile dysfunction Raposo FJ, Polonini HC, Ferreira AO, Raposo NRB, Brandao MAF AAPS PharmSciTech, 18(7), 2824-2831 This study aimed to develop a device to produce transdermal patches in compounding pharmacies. Tadalafil could permeate to the viable epidermis and dermis (5.7%). The created device produced homogeneous patches of tadalafil, showing feasibility in individualized therapy for the treatment of erectile dysfunction. Read more
OrPhyllo | 2017 Orodispersible films for compounding pharmacies Ferreira AO, Brandao MAF, Raposo FJ, Polonini HC, Raposo NRB International Journal of Pharmaceutical Compounding, 21(6), 454-461 This article aims to explore some of the basics on orodispersible film and the main possible preparations to be developed in compounding pharmacies worldwide. Read more
Syrspend SF | 2017 Suspensions as a valuable alternative to extemporaneous compounded capsules Dijkers E, Nanhekhan V, Thorissen A, Polonini HC International Journal of Pharmaceutical Compounding, 21(2), 171-175 The objective of this study was to determine the variation in content of 74 different APIs and compare it with existing literature on the content uniformity of extemporaneous prepared capsules. Compounded oral liquids show little variation, appearing to be a suitable alternative when compounding individualized medications for patients. Read more SEE PRODUCT